Literature DB >> 11095410

Prognostic factors of overall survival in patients with delayed lymph node dissection for cutaneous malignant melanoma.

L Kretschmer1, K P Preusser, W C Marsch, C Neumann.   

Abstract

To date, no study of melanoma patients who have undergone delayed lymph node dissection (DLND) has focused on the independent prognostic factors of overall survival, as calculated from surgery on the primary. Using Kaplan-Meier estimates and Cox's proportional hazard model, the significance of prognostic factors was evaluated in 173 patients who developed clinically apparent regional lymph node metastases. When calculated from excision of the primary tumour (median Breslow thickness 3.0 mm), the median survival was 38 months. When calculated from DLND, the median survival was 19 months. Multifactorial analysis revealed that the number of nodes involved at the time of DLND significantly affected both survival calculated from primary tumour excision (P = 0.0002) and survival calculated from DLND (P < 0.0001). In contrast, the well-known risk factors of primary melanoma did not significantly influence overall survival or survival after DLND. However, the remission duration between surgery on the primary and DLND clearly depended on epidermal ulceration (P = 0.001), Breslow thickness (P = 0.009) and the site of the primary melanoma (P = 0.048). Thus, in patients submitted to DLND, the risk factors of primary melanoma influence the early period of the disease, until metastatic lymph nodes become palpable. With regard to overall survival, only the extent of nodal disease determines the prognosis of these patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11095410     DOI: 10.1097/00008390-200010000-00011

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  2 in total

1.  Melanoma patients with unknown primary site or nodal recurrence after initial diagnosis have a favourable survival compared to those with synchronous lymph node metastasis and primary tumour.

Authors:  Benjamin Weide; Christine Faller; Margrit Elsässer; Petra Büttner; Annette Pflugfelder; Ulrike Leiter; Thomas Kurt Eigentler; Jürgen Bauer; Friedegund Meier; Claus Garbe
Journal:  PLoS One       Date:  2013-06-25       Impact factor: 3.240

2.  Prognostic factors of melanoma patients with satellite or in-transit metastasis at the time of stage III diagnosis.

Authors:  Benjamin Weide; Christine Faller; Petra Büttner; Annette Pflugfelder; Ulrike Leiter; Thomas Kurt Eigentler; Jürgen Bauer; Andrea Forschner; Friedegund Meier; Claus Garbe
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.